Vaccine Info


UB-311, a novel synthetic peptide vaccine targeting beta amyloid (Aβ) in the treatment of Alzheimer's disease.

Currently completed a Phase 2a clinical trial study.  

The top-line Phase 2a data met the primary aims of safety and immunogenicity with a 96% response rate. All secondary endpoints - including Amyloid PET burden, CDR-SB, ADCS-ADL, ADAS-Cog and MMSE - pointed directionally in favor of UB-311, though not statistically significant with the study sample size.

April 10th, 2019